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Abstract 
 
Cancer susceptibility is essentially attributable to multiple low-penetrance genes. Using 
interspecific consomic and congenic mice between the tumour-resistant SEG/Pas and 
the tumour-sensitive C57BL/6J strains, a region on chromosome 19 involved in the 
genetic resistance to γ-irradiation-induced T-cell lymphomas (Tlyr1) has been 
identified. Through the development of non-overlapping sub-congenic strains, it has 
been further demonstrated that Anxa1 may be a candidate resistance gene on the basis of 
its differential expression in thymus stroma cells after γ-radiation exposure. In addition, 
thymus-stroma cells of thymic lymphomas exhibited a significant reduction in the 
expression levels of Anxa1. Interestingly, the activity of Anxa1 relies on prostaglandin 
E2 (PGE2) induction that brings about apoptosis in thymocytes. In fact, in vitro 
transfection experiments revealed that PGE2 production was enhanced when HEK 293 
cells were transfected with full-length cDNAs of Anxa1, with PGE2 production in the 
cells transfected with the allele of the resistant strain (Anxa1Tyr) being higher than that 
in cells transfected with the allele of the susceptible strain (Anxa1Phe). Furthermore, the 
presence of this compound in the medium induced apoptosis of immature 
CD4+CD8+CD3low cells in a dose-dependent manner. These results improve our 
knowledge of the molecular mechanisms triggering T-cell lymphoblastic lymphoma 
development, while highlighting the relevance of the stroma in controlling genetic 
susceptibility, and the use of PGE2 as a new therapeutic approach in T-cell 
haematogical malignancies. 
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Introduction 
There is convincing evidence from twin studies that the risk of cancer in humans 
has a strong genetic component (1). While rare highly penetrant germ-line mutations in 
tumour suppressor genes strongly predispose to familial forms of cancer, it is also 
known that a large proportion of cancer risk is attributable to multiple common alleles 
of minor susceptibility genes, sometimes referred to as low-penetrance genes (2). For 
such reason, the identification of genes capable of modifying individual tumour 
susceptibility is a main issue for understanding the genetic basis of cancer 
predisposition.  
The detection of genetic variants with weak phenotype effects in humans is 
difficult because cancer susceptibility does not in general segregate as single Mendelian 
traits. The genetic heterogeneity and variable aetiology of carcinogenesis in humans 
adds a further difficulty to this challenge. On the other hand mouse models, and in 
particular those making use of congenic strains have been shown to have a bearing on 
the identification of cancer susceptibility genes (3, 4). Although more than one hundred 
cancer susceptibility loci have been mapped in mice (5), relatively few of these have 
been translated into specific genes (6-10).  
Genetic loci controlling susceptibility to ionizing radiation-induced mouse 
thymic lymphomas have been previously mapped at chromosomes 4, 5, and 16 (refs. 
11-13). A study of the γ-radiation-induced thymic lymphoma (RITL) predisposition 
with the help of inter-specific consomic strains (ICS) led us to identify a tumour-
resistance locus on mouse chromosome 19 (Tlyr1) (14). By analyzing congenic mice 
derived from ICS for chromosome 19, we mapped Tlyr1 to a region of about 14 Mb 
flanked by D19Mit85 and D19Mit13 microsatellite markers. Tlyr1 lies adjacent to 
another distal RITL susceptibility region (15), and excludes the candidacy of some 
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genes like Pten (16) and Fas (17, 18) for which a role in RITL predisposition has been 
already proposed. 
In this paper we focus on Tlyr1, emphasizing the identification of putative 
candidate genes through the generation of non-overlapping subcongenic strains. We 
examined the connections between the different subcongenic strains and thymic 
lymphoma resistance, and explored the candidacy of specific genes through the analysis 
of their expression patterns in an early response to γ-irradiation and during RITL 
development. We found that RITL resistance is clearly influenced by the levels of 
expression in thymus-stroma cells of the gene encoding the annexin A1 protein (Anxa1) 
that is located at the proximal region of Tlyr1. 
 
Material and methods 
Mice. C57BL/6J mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME, USA). Mice congenics for SEG/Pas (Mus spretus) in the critical Tlyr1 
region (named as B6.Tlyr1SEG) were generated as we described elsewhere (19). Animal 
experiments were carried out according to the European Commission Guidelines 
(Directive 86/609/CEE) on the use of laboratory animals. 
  
Genotyping of subcongenic mice. Mice were genotyped for 14 microsatellite 
markers arranged along the Tlyr1 region. These markers were amplified using primers 
and PCR conditions obtained from the Mouse Genome Database1.   
 
Thymic lymphoma induction. Mice were exposed to whole-body fractionated 
(4 x 1.75 Gy) γ-irradiation at weekly doses, starting at 4-5 weeks of age. Treated mice 
were observed at weekly intervals beginning 12 weeks after completion of γ-irradiation 
 5
treatment and up to 25 weeks (the latency period for these tumours), and phenotyped for 
the presence/absence of thymic lymphomas as we previously described (14).   
 
Thymic cell fractionation. Thymus samples were mechanically dispersed and 
strained through a nylon mesh (BD Biosciences) to isolate the thymocytes. Stroma-
enriched cell fractions were then obtained by collagenase digestion as previously 
described (20). Stromal cells (CD45-) were afterwards isolated by immunomagnetic 
separation using anti-CD45-conjugated paramagnetic micro-beads, following the 
manufacture’s instructions (Miltenyi Biotech).  
 
Standard RT-PCR Transcriptional expression of the genes mapped at the 
Tlyr1a region was carried out by conventional RT-PCR. The SuperScript First-Strand 
Synthesis System (Invitrogen) was used to perform RT-PCR reactions. The gene 
encoding the glucose-6-phosphate-1-dehydrogenase (G6pd) was used as an internal 
control. Supplementary table S1 shows the primer sequences used. The primers were 
designed by TibMolBiol (Berlin, Germany). RT-PCR products were visualised by direct 
ethidium bromide staining in 1.5% agarose gels. 
 
DNA sequencing. RNA was extracted from thymuses using Tripure Reagent 
(Roche). Based on the Anxa1 cDNA sequence2, a couple of primers were designed: 5’-
CTCTAAAAATGGCAATGGTATCAG-3’ (forward); 5’-
TTGCAGAATAGTTGGGATGT-3’ (reverse). Reverse transcription was performed 
using the Superscript First-Strand Synthesis System (Invitrogen), followed by PCR 
using the Expand High Fidelity PCR System (Roche) and the aforementioned primers. 
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cDNA sequencing reactions were performed on an ABI Prism 310 Automated 
Sequencer (Applied Biosystems). 
 
Quantitative real time RT-PCR. The quantification of the transcriptional 
levels of thymus-expressing genes was performed by real-time RT-PCR with a 
LightCycler instrument (Roche). RT-PCR reactions were carried out in total RNA using 
the one-step LightCycler SYBR Green I kit (Roche). The primers used were those 
described in Table S1. Relative expression values were calculated as the mRNA amount 
of each gene relative to that of G6pd (used as reference) and normalized to the relative 
expression of a non-treated thymus sample, using the LightCycler Relative 
Quantification software (Roche). 
 
 Loss of heterozygosity (LOH) analysis of Anxa1. PCR/SSCP analysis for LOH 
detection was performed using the primers: 5’-AAGGAGAAAGGGGACAGACG-3’ 
(forward) and 5’-AATAAAGGAACAGCATCGCC-3’ (reverse). After PCR, samples 
were mixed (1:1) with loading buffer containing 0.08N NaOH and 95% formamide. 
Samples were heated at 95ºC for 10 min, and subjected to 0.5xMDE (Mutation 
Detection Enhancement) polyacrylamide gels (BioWhitaker) in 0.6xTBE buffer. After 
electrophoresis, DNA fragments were silver-stained using a standard protocol.  
 
Western blotting. Proteins were extracted from cell lysates using TriPure 
Reagent (Roche), separated on 8-12 % SDS-PAGE and electrotransferred to 
nitrocellulose membranes (BioRad). They were then incubated with anti-ANXA1 
antibody (R&D Systems) at a 1:5000 dilution. Detection of β-actin with a monoclonal 
anti-β-actin antibody (Sigma), at a 1:10000 dilution, was used as control. Next, an 
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incubation with secondary antibodies coupled to horseradish peroxidase was carried out 
using a donkey anti-goat antibody for ANXA1 (Santa Cruz Biotechnology) and a sheep 
anti-mouse antibody for β-actin (GE Healthcare) at a 1:1000 dilution. Bands were 
detected using the ECLTM Western Blotting Detection kit (GE Healthcare). Protein 
levels were densitometrically quantified, using the Scion Image program (Scion Corp), 
and calculated as the amount of ANXA1 protein relative to that of β-actin. These were 
then normalized to the amount of ANXA1 in a non-treated thymus sample. 
 
Cloning of Anxa1 cDNA sequences and transient transfections. Purified 
DNA fragments containing the Anxa1 full-length cDNA were doubly digested with 
HindIII and BamHI and cloned into pcDNA3 plasmid (Invitrogen). The primers used 
for cloning were (generated restriction sites underlined): Anxa1HindIII: 5’-
AAGCTTCTCTAAAAATGGCAATGGTATCAG-3’ (forward); Anxa1BamHI: 5’-
GGATCCTTGCAGAATAGTTGGGATGT-3’ (reverse). Using the Expand High 
Fidelity PCR System (Roche) and the aforementioned primers, a fragment of 1081 bp, 
which includes the entire coding sequence, was amplified. Transfections were done in 
human embryonic kidney (HEK) 293 cells using lipofectamine (Invitrogen). HEK 293 
cells were cultured in DMEM, supplemented with 10% FBS, 2mM L-glutamine (all 
from Invitrogen), 0.1mg/ml ampicillin (Roche), and 64μg/ml gentamicin (Sigma). The 
mouse thymic epithelial cell line 427 (kindly provided by Dr. Barbara Knowles) was 
used as control in Western blots to identify the mouse form of ANXA1 (21).  
 
Determination of prostaglandin E2 (PGE2) production by transfected cells. 
PGE2 was determined in cell culture supernatants by an ELISA assay using the ACE 
competitive EIA kit (Cayman Chemical). In this assay the target (PGE2) competes with 
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a PGE2-acetylcholinesterase (ACE) conjugate (PGE2 tracer) for a limited amount of 
PGE2-monoclonal antibody attached to the well. Both HEK 293 cells and supernatants 
were recovered 24h after transfection. PGE2 concentrations were determined 
spectrophotometrically by measuring the amount of PGE2 tracer bound to the well, 
which is inversely proportional to the amount of free PGE2.  
 
T-Cell cultures and PGE2 treatments. Freshly isolated mouse thymocytes and 
mouse Thy278 T-cells (kindly provided by Dr. Ingo Schmitz, University of Düsseldorf, 
Germany) were grown in RPMI-1640 supplemented with 10% FBS, 100U/ml penicillin, 
100μg/ml streptomycin, 2mM L-glutamine (all from Invitrogen), 1mM sodium piruvate, 
1% non essential amino acids (both from Biowhittaker), and 0.05 mM 2-
mercaptoethanol (Merck). Human Karpas-45, Peer, and Jurkat T-cells were obtained 
from the German Collection of Microorganisms and Cell Cultures (DSMZ), and 
cultured as we described elsewhere (17). PGE2 (Cayman Chemical) was added to the 
culture medium at the time of plating. Serial dilutions of PGE2, ranging from 0.01 to 
100 μM, were used. Cells were harvested at 8 hr, 16 hr and 24 hr after treatment. 
 
Immunofluorescence staining and flow cytometry analysis. Freshly isolated 
thymocytes from non-treated and 1.75 Gy-treated thymuses were examined by 
immunofluorescence staining and flow cytometry analysis. We used fluorescein 
(FITC)-conjugated rat anti-mouse CD4 and phycoerythrin (PE)-conjugated rat anti-
mouse CD8a (both from BD Pharmigen) for a two-colour flow analysis of CD4- and 
CD8-positive cells on a Coulter Epics XL-MCL flow cytometer (Beckman Coulter). In 
addition, biotin-conjugated rat anti-mouse CD4, PE-conjugated rat anti-mouse CD8a, 
and FITC-conjugated hamster anti-mouse CD3e (all from BD Pharmigen) were used for 
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a three-colour flow analysis on a FACSCalibur flow cytometer (BD Biosciences). All 
antibodies were used at a 1: 100 dilution.  
 
Quantification of apoptosis by TUNEL assay. Cells were fixed in 3.7% 
formaldehyde in PBS for 20 min at 4ºC and then permeabilized in 0.1% Triton X-100 
sodium citrate for 5 min at 4ºC. Staining was performed in suspension cells by TUNEL 
assay using a commercially avalaible kit (Roche). The percentage of TUNEL positive 
cells was determined using either a Coulter Epics XL-MCL flow cytometer or a 
FACSCalibur flow cytometer.  
 
Cell cycle analysis by propidium iodide (PI) flow cytometry. Cells were 
harvested and fixed in ice-cold 70% ethanol. Upon staining, cells were suspended in 
PBS containing 50μg/ml of RNase A (Sigma) for 15 min at room temperature. Last, PI 
(Sigma) staining solution at a final concentration of 50μg/ml was added. The DNA 
content was estimated using a Coulter Epics XL-MCL flow cytometer or a 
FACSCalibur flow cytometer. 
 
Statistical analysis. The differences in RITL incidence between groups were 
examined for statistical significance by Chi-square (χ2) test. Probability (P) values of 
<0.0125 (Bonferroni correction (α/N), α being = 0.05 and N (number of comparisons) = 
4), were considered significant. The Kolgomorov-Smirnov test was used to test 
expression data sets for normality, and the Levene’s test was used for homogeneity of 
variances. For multiple comparisons, statistical significance was determined using a 
one-way ANOVA analysis with a Bonferroni comparison post-test. All statistical tests 
were carried out using the SPSS software (version 14.0). 
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Results 
High resolution mapping of Tlyr1 
 A high resolution genetic map of Tlyr1 was constructed to aid in the identification 
of candidate RITL resistance genes for this region. Initially, we worked on the selection 
of nested recombinant haplotypes (NRHs) for Tlyr1 by backcrossing male mice 
heterozygous congenics for SEG/Pas (Mus spretus) in this region (named as 
(B6.Tlyr1SEG x B6) F1) with females of the susceptible C57BL/6J strain, followed by a 
final intercross to reach homozygosity. We generated three different subcongenic strains 
(hereafter named as NRH1, NRH2 and NRH3), covering the entire Tlyr1 region, each of 
them carrying a non-overlapping SEG/Pas chromosome segment (Tlyr1a, Tlyr1b, and 
Tlyr1c) (Figure 1A). In order to analyze RITL incidence, mice of congenic B6.Tlyr1SEG 
and subcongenic NRH strains, as well as C57BL/6J mice as reference, were subjected to 
fractionated sublethal whole body γ-irradiation (4 x 1.75 Gy). To exclude the well-
documented sex difference in RITL development (13), only treated females were 
analyzed. Although all of the three NRH regions contributed to a reduction of RITL 
incidence, the association was only conclusive for NRH1 (Figure 1A). These data 
allowed us to restrict our search to Tlyr1a, a SEG/Pas chromosome segment of about 
3.2 Mb delimited by the D19Mit41 and D19Mit96 markers.  
 
The gene encoding the annexin A1 protein is a putative candidate gene for Tlyr1  
 Once Tlyr1a was selected, an in silico analysis2 indicated nine annotated genes 
mapping to this region. Later on, we characterized the thymus expression specificity of 
all these genes by RT-PCR. Only six of these genes showed expression in the thymus 
(Figure 1B). To find out whether there existed a pattern of differential gene expression 
in an early response to 1.75 Gy of γ-irradiation, the transcriptional expression of these 
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genes was determined by quantitative real time RT-PCR in thymuses from NRH1 and 
C57BL/6J mice. Only the Anxa1 gene was shown to exhibit a significant differential 
expression (Figure 1C). Apart from quantitative differences, the comparative analysis of 
the coding sequence of Anxa1 between the NRH1 and the C57BL/6J strains evidenced a 
non-conservative T689A single nucleotide polymorphism (GeneBank accession number 
EU684130) that resulted in a Tyr230Phe variation in the ANXA1 protein, which might 
reflect a different biological activity of both alleles (Anxa1Tyr in NRH1 and Anxa1Phe in 
C57BL/6J). The accumulation of qualitative and quantitative differences clearly 
indicates that Anxa1 could be a good candidate gene for the Tlyr1 region. 
 
There is a higher expression of Anxa1 in the thymus stroma of NRH1 mice in early 
response to a single sub-lethal γ-ray dose 
 Since the thymus is a complex organ incorporating thymocytes and stromal cells, 
we analyzed the allele expression profiles of this gene in separate thymus-stroma cells 
and thymocytes. Notably, in non-treated mice, the Anxa1 gene was expressed in 
thymus-stroma cells (TSCs) whereas it was weakly perceptible in thymocytes (Table 1). 
In addition, treatments with a single sublethal dose (1.75 Gy) induced higher RNA 
levels of Anxa1 in TSCs from NRH1 mice as compared to C57BL/6J mice (Table 1). 
These results were confirmed at protein level (Table 1 and supplementary Figure S1).  
 
The expression of Anxa1 is also altered in the thymic stroma of T-cell 
lymphoblastic lymphoma-bearing mice 
 Exposure of mice to fractionated 1.75 Gy doses of γ-irradiation elicits thymic 
lymphomas, in particular T-cell lymphoblastic lymphomas, which are characterized by 
uncontrolled expansion of immature thymocytes (22). To get further insight into the role 
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of Anxa1 in RITL development, we examined the expression of this gene in the two cell 
fractions from thymuses of treated mice that developed thymic lymphoma (RITL-
bearing mice) (in all cases T-cell lymphoblastic lymphomas) as well as from thymuses 
of treated mice that did not develop thymic lymphoma after the latency period. 
Irrespective of their genotype, TSCs of RITL-bearing mice exhibited a significant 
reduction in the mRNA levels of Anxa1 compared with the values observed in TSCs 
from non-treated control mice (Table 1). By contrast, no differences were observed in 
TSCs from irradiated mice that did not develop thymic lymphomas after the latency 
period. The amount of ANXA1 protein was also found to be significantly reduced in 
TSCs from all the RITL-bearing mice analyzed (Table 1 and Figure S1).  
 It should be stressed that sequencing analysis of Anxa1 performed on its cDNA 
did not reveal any mutation in the tumour samples (data not shown). However, LOH 
studies with this gene revealed frequent allele losses in tumours of NRH1 heterozygous 
mice (10 out of 22, 45.4%), indicating that the reduction of Anxa1 expression found in 
thymic lymphomas could be attributed, at least in part, to the deletion of one allele 
(Figure S2). 
 
γ-Irradiation results in differential G1 arrest and apoptosis in thymocytes of NRH1 
mice 
 Given that ionizing irradiation results in cell cycle arrest and apoptosis induction, 
we wondered whether different levels of Anxa1 expression, detected in TSCs of 
thymuses from 1.75-Gy-treated NRH1 and C57BL/6J mice, could be involved in 
causing differences in the cell cycle distribution and/or the apoptotic response of their 
respective thymocyte fractions. To this end, we studied the progression through the cell 
cycle and the apoptosis rate in freshly isolated thymocytes from these mice collected 24 
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hr after γ-ray treatment. Cell cycle was analyzed through flow cytometry following the 
staining of cells with PI (Figure 2A). We detected a significant increase of PI positive 
NRH1 thymocytes at the G1 phase by comparison with those of the C57BL/6J, 
evidencing a differential effect of γ-irradiation in G1 arrest between the two strains. 
Interestingly, this G1 arrest was also accompanied by a significant increase in the sub-
G1 population of NRH1 thymocytes, compared to that of the C57BL/6J strain.  
Next, we studied the induction of apoptosis by TUNEL assay and flow 
cytometry (Figures 2B). The treatment with 1.75 Gy significantly induced more 
thymocyte apoptosis in NRH1 than in C57BL/6J mice. The percentage of TUNEL 
positive cells detected in γ-treated thymocytes was closely similar to sub-G1 cell 
percentages in the same samples (Figures 2A-B), indicating that the sub-G1 fraction 
may basically consist of apoptotic thymocytes, as pointed out elsewhere (23). 
Interestingly, the Anxa1 expression levels in TSCs correlated positively with either the 
rate of thymocyte arrest at the G1 phase of the cell cycle (R2=0.948, P=0.018) or with 
thymocyte apoptosis (R2=0.963, P=0.013).  
It is known that immature thymocytes, particularly CD4+CD8+ cells, readily 
undergo apoptosis in response to γ-irradiation (24). If Anxa1 expression and thymocyte 
apoptosis are two events positively correlated, then increased expression levels of 
Anxa1 should specifically result in a reduction of the number of CD4+CD8+ cells. We 
found a significant higher depletion of 1.75 Gy γ-treated CD4+CD8+ thymocytes in 
NRH1 mice as compared to C57BL/6J (Figures 2C-D) that might reflect the different 
levels of Anxa1 expression existing in the TSCs of both strains (R2=0.956, P=0.02).  
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The Anxa1Tyr allele induces a higher production of PGE2 in transfected cells 
 Since thymic epithelial cells transfected with Anxa1 cDNA increase the 
production of PGE2 (25), and this molecule is able to induce apoptosis of immature 
CD4+CD8+ thymocytes (26), we performed in vitro experiments using human HEK 
293 cells transfected with an expression vector (pcDNA3) containing the full length 
cDNA of  mouse Anxa1 in either the Anxa1Tyr or Anxa1Phe allelic variant. We used these 
cells for three main reasons. First, they produce very low levels of endogenous ANXA1 
protein. Second, the human form of ANXA1 can be easily distinguished from the mouse 
one. Finally, HEK 293 cells are extremely easy to culture and transfect. The 
functionality of each allele was determined by quantifying the amount of extracellular 
PGE2 produced by the transfected HEK 293 cells in a competitive ELISA assay. The 
production of ANXA1 protein by the transfected cells was examined by Western blot 
analysis as a quality control measure of transfection. As shown in Figure 3A, the 
amount of ANXA1 protein increased ∼2.5-fold in the ANXA1-overexpressing cells 
with no significant differences between the two types of Anxa1 transfectants. However, 
PGE2 production in Anxa1Tyr-transfected cells was significantly higher (∼1.3-fold 
increase) than in Anxa1Phe-transfected cells (Figure 3B). Since the amounts of ANXA1 
protein were kept constant, the differences in the production of PGE2 may be attributed 
to a distinct biological activity of the two Anxa1 alleles.  
 
PGE2 induces apoptosis in immature CD4+CD8+CD3low thymocytes 
 To find out whether a causal link exists between the amount of PGE2 and the 
ability of primary thymocytes to undergo apoptosis, we first analyzed the apoptotic 
response of primary C57BL/6J thymocytes in vitro by TUNEL assays after being 
subjected to serial dilutions of PGE2 ranging from 0.01 to 100 μM. To select the most 
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appropriate conditions, we monitored this process at 8 hr, 16 hr and 24 hr after 
treatment. The results showed that C57BL/6J PGE2-treated thymocytes significantly 
underwent more apoptosis than those in non-treated cultures, these differences being 
highest at 16 hr (Figure S3). The effect of PGE2 on thymocyte apoptosis became 
significantly evident at a concentration as low as 0.01 μM, was similar at 0.1 and 10 
μM, and was much higher at 100 μM (Figure 4A). Our data also revealed that the 
administration of a given dose of PGE2 in the medium produced similar induction of 
apoptosis in primary NRH1 thymocytes (data not shown). Next, we investigated which 
thymocyte subpopulations were affected by exposure to PGE2. To this end, cultures of 
primary C57BL/6J thymocytes were treated during 16 hr with PGE2 and then analyzed 
by flow cytometry to determine the expression of CD4, CD8 and CD3 cell surface 
antigens. PGE2 administration triggered a selective loss of immature 
CD4+CD8+CD3low thymocytes (Figure 4B). Since it had been suggested that PGE2 
might also interfere in the process of lymphoid cells by mediating growth arrest (27), 
we also explored this possibility by determining the number of thymocytes at different 
phases of the cell cycle. Compared to the control, PGE2-treated primary thymocytes did 
not show changes in cell cycle distribution, but they did exhibit statistically significant 
increases in the number of cells at the sub-G1 region in a dose-dependent manner 
(Figures 4C).  
 To demonstrate whether the induction of apoptosis by PGE2 was also functional 
in transformed thymocytes, we analyzed apoptosis events in the murine Thy278 thymic 
lymphoma cell line, consisting of immature CD4+CD8+ thymocytes (28). Significant 
apoptosis was only detected 24 hr after treatment with 100μM of PGE2 (Figure 5A). 
Changes in cell cycle distribution of Thy278 cells were only evident after treatment 
with 100μM of PGE2, with a significant arrest of cells at the G1 phase (Figure 5B). 
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In order to investigate the ability of PGE2 to induce apoptosis and cell cycle 
arrest in human T-lymphoma cells, we analyzed three T-acute lymphoblastic leukaemia 
(T-ALL) cell lines, which represent different stages of T-cell differentiation: Karpas-45 
(CD4+CD8+CD3-), Peer (CD4+CD8+CD3+) and Jurkat (CD4+CD8-CD3+). 
Significant variations in the apoptotic rate were only observed in Karpas-45 cells 24 hr 
after treatment with 100μM of PGE2 (Figure 5A). In this case, the induction of 
apoptosis was accompanied by a significant arrest of cells at G2/M (Figure 5B). 
 
Discussion 
 It is widely known that minor susceptibility genes are an essential component of 
heritability on individual resistance/susceptibility to cancer (2, 6). In this paper, the use 
of NRH-subcongenic mice between a thymic-lymphoma-susceptible strain (C57BL/6J) 
and a thymic-lymphoma-resistant one (SEG/Pas) allowed us to identify a critical region 
on the proximal part of mouse chromosome 19 that confers significant resistance to γ-
radiation induced thymic lymphomas. Due to differential expression profiles in an early 
response to γ-irradiation and reduced expression in thymic lymphomas we proposed 
Anxa1, whose locus maps to the critical region, as a possible thymic-lymphoma-
resistance candidate gene (Figure 1). Its candidacy was also supported by the fact that 
the allelic variants from susceptible and resistant mice encode protein variants involving 
functional domains of the ANXA1 protein. 
ANXA1 has been described as a calcium and phospholipid-binding protein that 
participates in a variety of inflammatory pathways, on the control of cell proliferation, 
and in the regulation of death signalling (29), but the mechanisms through which this is 
accomplished in the thymus remain to be elucidated. It is known that thymocyte 
apoptosis is mediated by thymic epithelial cells, which constitute the major component 
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of the so-called thymus stroma (30). We hereby report that Anxa1 is expressed 
exclusively by thymus-stroma cells (Table 1) and that thymocytes from γ-treated NHR1 
subcongenics and C57BL/6J mice undergo G1 arrest and apoptosis in an Anxa1-dose 
dependent manner (Figures 2A-B). This is in agreement with previous findings 
evidencing that thymic microenvironmental factors can control thymocyte apoptosis 
from irradiated mice after preventive treatments for thymic lymphoma (31). Consistent 
with published studies (32, 33), we found that CD4+CD8+ cells are the most susceptible 
thymocytes to radiation-induced apoptosis. Interestingly, the degree of CD4+CD8+ cell 
reduction differs between the NRH1 and C57BL/6J strains (Figure 2C). Since the more 
resistant strain (NHR1) is the one exhibiting the highest levels of Anxa1 expression and 
undergoing the highest rate of cell cycle arrest and apoptosis, these results suggested a 
possible causal relationship between levels of Anxa1 expression, cell cycle arrest and 
apoptotic induction. This led us to wonder about the mechanisms of cell cycle arrest and 
apoptosis induced by Anxa1. 
Previous studies reported that ANXA1 may increase the production of PGE2 
(25). It is also known that PGE2 is able to induce thymocyte apoptosis and may 
interfere with the proliferation of thymocytes by mediating growth arrest (26-27). These 
premises led us to initially evaluate the ability of NRH1-Anxa1Tyr and C57BL/6J-
Anxa1Phe alleles as potential inducers of PGE2. In vitro transfection experiments 
revealed that PGE2 production was, in fact, enhanced when epithelial HEK 293 cells 
were transfected with Anxa1 cDNA, and that the cDNA from the Anxa1Tyr allele was 
able to induce a far higher amount of PGE2 than that of Anxa1Phe (Figure 3). Thus, it 
seems reasonable to think that the sequence variations existing between the two alleles 
are responsible, at least in part, for the differences in PGE2 production.  
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Having confirmed that Anxa1 was able to induce PGE2 production, we next 
investigated whether primary thymocytes underwent cell cycle arrest and apoptosis as 
an outgrowth of differences in the production of PGE2 by thymus-stroma cells. 
Quantification of apoptosis in primary thymocytes revealed that these cells died upon 
PGE2 exposure at physiological (0.01μM) and non-physiological (0.1-100μM) 
concentrations in a dose-dependent manner (Figure 4A). In addition, the effect of these 
PGE2 concentrations on apoptosis involved a selective and progressive reduction of 
CD3 low expressing CD4+CD8+ thymocytes (Figure 4B), suggesting a CD3-dependent 
rank of action of PGE2-induced apoptosis. Our data confirm previous experiments 
reporting apoptosis induction in CD4+CD8+CD3low thymocytes after an in vivo 
administration of PGE2 in C57BL/6J mice (26). Since mouse CD4+CD8+ thymic 
lymphoma Thy278 cells express CD3 at intermediate levels (28) and human karpas-45 
are human CD4+CD8+CD3- T-lymphoma cells (34), it is not surprising that 
physiological concentrations of PGE2 had no effect on these cells. 
Our results are also in line with the existence of distinct apoptotic pathways 
operating alternatively during the development of double positive thymocytes. For 
example, mouse double positive PD1.6 thymic lymphoma cells (CD4+CD8+CD3+) 
undergo apoptosis thymic epithelial cell-derived glucocorticoids-mediated apoptosis 
(35), whereas Thy278 cells die by apoptosis upon T-cell receptor/CD3 stimulation (27). 
We have recently demonstrated that the Cd95/Cd95L system mediates induced 
apoptosis of immature thymocytes and thymic lymphomas cells after exposure to γ-
irradiation (18).  
At the same time, it is worth noting that PGE2 treatment is able to induce G1 
arrest in the Thy278 cell line, but G2 arrest in Karpas-45 cells (Figure 5B). These 
results indicate that the cellular response of transformed T-cells to PGE2 is quite 
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complex, and suggest the existence of distinct molecular mechanisms of cell cycle arrest 
in different cell lines. It has been reported that differences in the gene expression profile 
may be related to the activation of a specific cell cycle arrest (at G1 or at G2) in human 
malignant B-lymphocyte lines after exposure to ionizing irradiation (36). The existence 
of a distinct gene status in the transformed Thy278 and Karpas-45 cells might help to 
explain the differences found in the cell cycle distribution. Further studies will be 
necessary to confirm this hypothesis. 
As regards to cancer, the Anxa1 gene has been found to be frequently down-
regulated or up-regulated in many human solid tumours (37-43), as well as in B-cell 
lymphomas (44). Remarkably, alterations of this gene were always restricted to the 
tumour cells per se, but this does not seem to be the case in RITL samples, where the 
expression of Anxa1 was altered only in the tumour-associated stroma cells (Figure 2). 
Several studies point to the engagement of the tumour-associated stroma in the 
development of certain solid tumours (45-47). A recent work pointed out the importance 
of bone marrow stromal cells in order to prevent the apoptosis of lymphoma cells in 
non-Hodgkin´s lymphoma (48). In mice, we have demonstrated that γ-irradiation is able 
to induce T-cell lymphoblastic lymphomas in the setting of a gene-altered thymic 
microenvironment (49). The results reported here highlight the engagement of the 
stroma in the development of T-cell haematological malignancies. The contribution of 
tumour-stroma sensitivity as a determinant of radiation-induced tumour-growth delay 
has been reported elsewhere (50). From our results it seems reasonable to postulate that 
the expression of Anxa1, below a certain threshold level (as detected in RITL samples), 
could be favouring T-cell lymphomagenesis, and that its over-expression (as detected in 
response to a single sub-lethal dose of γ-rays) might have a protective role over 
surrounding thymocytes, enhancing their apoptotic signals. 
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In summary, we show here that ANXA1, a protein previously characterized as a 
mediator of the anti-inflammatory activity of glucocorticoids in the host defence 
system, might play a critical role in the induction of apoptosis of immature CD4+CD8+ 
thymocytes through the production of PGE2 by thymus-stroma cells. These results 
expand our understanding of the mechanisms underlying the genetic susceptibility to 
thymic lymphomagenesis, and open new perspectives for PGE2 as a potential drug in 
the therapy of T-cell haematological malignancies characterized by an uncontrolled 
proliferation of immature CD4+CD8+ thymocytes. 
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Table 1. Effect of γ-irradiation on Anxa1 expression in thymus-stroma cells and thymocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No TL represents irradiated mice that did not develop thymic lymphomas after completion of the latency period. TL denotes thymic lymphoma-bearing mice. 
Data are shown as the mean ± SD of normalized values obtained from three independent experiments. Statistically significant differences between the 
experimental groups were determined by a one-way ANOVA with a  Bonferroni multiple comparison test. 
a P<0.0001 compared with the  corresponding value of the control stromal RNA expression.  
b P<0.0001 compared with the corresponding value of the stromal RNA expression of 1.75Gy- irradiated C57BL//6J mice. 
c P<0.005 compared with the  corresponding value of the control stromal protein expression.  
d P<0.003 compared with the  corresponding value of the stromal protein expression of 1.75Gy- irradiated C57BL//6J mice. 
 
 
γ-Irradiation 
treatment 
Experimental 
group 
Cell  
type 
Anxa1 normalized RNA expression 
(mean ± SD) 
Size 
(N)  
ANXA1 normalized protein expression 
(mean ± SD) 
Size 
(N) 
None 
 
C57BL/6J (control) 
Thymus-stroma cells 3.53 ± 0.22 
3 
1.20 ± 0.26 
3 
thymocytes 0.20 ± 0.08 0.43 ± 0.09 
NRH1 
Thymus-stroma cells 3.64 ± 0.26 
3 
1.40 ± 0.17 
3 
thymocytes 0.16 ± 0.08 0.50 ± 0.10 
1 x 1.75 Gy 
C57BL/6J 
Thymus-stroma cells   7.43 ± 0.20 a
3 
  2.30 ± 0.21 c
3 
thymocytes 0.26 ± 0.07 0.44 ± 0.06
NRH1 
Thymus-stroma cells      9.39 ± 0.08 a, b
3 
     3.50 ± 0.31 c, d
3 
thymocytes 0.23 ± 0.07 0.50 ± 0.17
4 x 1.75 Gy 
C57BL/6J (No TL) 
Thymus-stroma cells 3.48 ± 0.31 
10 
1.06 ± 0.16 
5 
thymocytes 0.10 ± 0.06 0.34 ± 0.12 
C57BL/6J (TL) 
Thymus-stroma cells   2.43 ± 0.29 a
10 
  0.46 ± 0.14 c
5 
thymocytes 0.11 ± 0.08 0.39 ± 0.17
NRH1 (No TL) 
Thymus-stroma cells 3.30 ± 0.33 
10 
1.14 ± 0.19 
5 
thymocytes 0.10 ± 0.07 0.35 ± 0.14 
NRH1 (TL) 
Thymus-stroma cells   2.22 ± 0.27 a
10 
  0.49 ± 0.16 c
5 
thymocytes 0.08 ± 0.04 0.32 ± 0.15
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Legends of figures 
Figure 1.  Anxa1 is a putative candidate resistance gene for the Tlyr1 region.  
(A) Tumour incidence in Tlyr1 subcongenic mice. C57BL/6J segments are indicated 
with open rectangles. Black rectangles show the SEG/Pas segments. Chi-square values 
and associated P values were performed comparing the tumour incidence in congenic or 
subcongenic mice with that of C57BL/6J. (B) Thymus expression specificity of the 9 
genes located on Tlyr1a, was determined by RT-PCR. (C) Quantitative real-time RT-
PCR analysis of the six genes expressed in thymus. The results are shown as mean 
values ± SD of three independent experiments. Light grey-filled bars, non-treated 
thymus from C57BL/6J (used as controls). Black-filled bars, non-treated thymus from 
NRH1. open-filled bars, γ-treated (1.75 Gy) thymus from C5/BL/6J. Dark grey-filled 
bars, γ-treated (1.75 Gy) thymus from NRH1. Statistically significant differences were 
determined by a one-way ANOVA with a Bonferroni multiple comparison test. 
*P<0.0001. 
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Figure 2. Thymocytes of NRH1 and C57BL/6J γ-treated mice show differential G1 
arrest and apoptosis.  
(A) Representative PI flow cytometric cell cycle distribution plots. Non-treated 
C57BL/6J thymocytes were used as controls. aP<0.007, bP<0.004, cP<0.0001 compared 
with the corresponding value of control thymocytes. dP<0.026, eP<0.007, fP<0.002 
compared with the corresponding value of 1.75 Gy-γ-treated C57BL/6J thymocytes. (B) 
Representative experiment of apoptotis induction estimated by TUNEL assay. 
Horizontal bars indicate percentage of apoptotic cells. aP<0.0001 compared with the 
corresponding value of control C57BL/6J thymocytes; bP<0.002 compared with the 
corresponding value of 1.75 Gy-γ-treated C57BL/6J thymocytes. (C-D) Flow cytometry 
analysis of the expression of CD4 and CD8. DP: CD4+CD8+. SP4: CD4+CD8-. SP8: 
CD8+CD4-. aP<0.0001 compared with the corresponding value of control DP cells; 
bP<0.015 compared with the corresponding value of 1.75 Gy-γ-treated C57BL/6J DP 
cells (ANOVA with a Bonferroni post-test). Numbers under the plots in A and B are 
represented as a mean cell percentage ± SD of three independent experiments. 
Quantitative data above the plots in C represent mean absolute values ± SD of three 
independent experiments. Statistically significant differences were determined by 
ANOVA with a Bonferroni post-test. 
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Figure 3. The Anxa1Tyr- and Anxa1Phe-transfected HEK 293 cells produce distinct 
amounts of PGE2.  
(A) Western blot analysis of ANXA1 in HEK 293 cells. Control, non-transfected cells. 
pcDNA3, cells transfected with empty vector. Anxa1Phe, cells transfected with the 
Anxa1-cDNA from C57BL/6J mice. Anxa1Tyr , cells transfected with the Anxa1-cDNA 
from NRH1 mice. Mouse thymic-epithelial-cell line 427 was used as control. Data 
correspond to a representative experiment out of three which gave similar results. 
mANXA1, mouse ANXA1. hANXA1, human ANXA1. (B) Levels of PGE2 production 
by control and transfected HEK 293 cells. Culture supernatants were analyzed for PGE2 
secretion by ELISA assay. The results are shown as the mean ± SD of three independent 
experiments. Statistically significant differences were determined by a one-way 
ANOVA with a Bonferroni multiple comparison test. *P<0.004. 
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Figure 4. PGE2 causes the selective loss of mouse primary CD3lowCD4+CD8+ 
thymocytes through the induction of apoptosis  
(A) Analysis of apoptosis by TUNEL assay and flow cytometry. aP<0.003, bP<0.0001, 
compared with the corresponding value of non-treated thymocytes (control); cP<0.0001, 
compared with the corresponding value of thymocytes treated with 0.01 μM of PGE2; 
dP<0.0001, compared with the corresponding value of thymocytes treated with 100 μM 
of PGE2. (B) Flow cytometry analysis of the expression of CD3, CD4 and CD8. DP, 
CD4+CD8+. SP4 CD4+CD8-. SP8, CD4-CD8+. Black-filled bars, CD3-. Light grey-
filled bars, CD3low. Open-filled bars, CD3+. aP<0.0001, compared with the 
corresponding value of control thymocytes; bP<0.037, cP<0.0001, compared with the 
corresponding value of thymocytes treated with 0.01 μM of PGE2; dP<0.0001, 
compared with the corresponding value of thymocytes treated with 10 μM of PGE2; 
eP<0.0001, compared with the corresponding value of thymocytes treated with 100 μM 
of PGE2. (C) Cell-cycle distribution analysis by PI flow cytometry. Black-filled bars, 
Sub-G1. Light grey-filled bars, G1. Open-filled bars, S. Dark grey-filled bars, G2/M.  
aP<0.014, bP<0.0001, compared with the corresponding value of control thymocytes; 
cP<0.0001, compared with the corresponding value of thymocytes treated with 0.01 μM 
of PGE2; dP<0.0001, compared with the corresponding value of thymocytes treated 
with 100 μM of PGE2. Histograms represent mean cell percentages ± SD of three 
independent experiments. Statistically significant differences were determined by 
ANOVA with a Bonferroni post-test. 
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Figure 5.  Induction of apoptosis and cell-cycle arrest in mouse Thy278 and human 
Karpas-45 T-lymphoma cells by high doses of PGE2 
(A) Analysis of apoptosis by TUNEL assay and flow cytometry in Thy278 cells (upper 
row) and Karpas-45 cells (lower row). aP<0.0001, compared with the corresponding 
value of non-treated cells (control). (B) Cell cycle distribution analysis by PI flow 
cytometry in Thy278 cells (upper row) and Karpas-45 cells (lower row). Black-filled 
bars, Sub-G1. Light grey-filled bars, G1. Open-filled bars, S. Dark grey-filled 
bars, G2/M. aP<0.0001, compared with the corresponding value of control cells. 
Histograms represent mean cell percentages ± SD of three independent experiments. 
Statistically significant differences were determined by ANOVA with a Bonferroni 
post-test. 
 
 
 





